Tertiary treatment for psychiatric comorbidity in headache patients by unknown
The presence of significant and confounding psychiatric
comorbidity is greater in patients attending headache clin-
ics than in headache patients from the general population.
Both tension-type headache (TTH) and migraine without
aura are associated with psychiatric disorders in a great
number of Italian patients (respectively, 77.8% and
56.4%). The most recurrent cluster of psychiatric disor-
ders was anxiety (52% and 39.2% respectively), followed
by mood disorders (36% and 23%) and, to a lesser degree,
somatoform disorder (21% and 21.6%) [1, 2]. Psychiatric
comorbidity was more frequent in the chronic than in the
episodic form of TTH [1]; on the other hand, it is well
known that psychological factors may play an important
role in both peripheral and central mechanisms of sensiti-
sation that are in turn responsible for transformation of
episodic headache into chronic headache.
The recognition of a psychiatric comorbidity is
mandatory for accurate management of the patient
because it prevents clinicians from using a drug that might
be dangerous for a misdiagnosed psychiatric disturbance
and often permits medication that can efficaciously con-
trol both headache and psychiatric disorders.
So, the association of depressive symptoms has to be
taken into account when deciding to start a migraine pro-
phylaxis with flunarizine or beta-blockers in worsening
mood disorders.
With regard to depression-related headache, it is well
known that antidepressive drugs can improve migraine as
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Abstract The presence of signifi-
cant and confounding psychiatric
comorbidity is greater in patients
attending headache clinics than in
headache patients from the general
population. The frequent comorbid-
ity of headache with generalized
anxiety disorder can take advantage
of the administration of benzodi-
azepines. With regard to depres-
sion-related headache, it’s well-
known that the antidepressive drugs
can improve migraine as well as
tension-type headache.
Antiepileptic drugs  give one more
good opportunity. The recognition
of a psychiatric comorbidity is
mandatory for an accurate manage-
ment of the patient beacause pre-
vents the clinicians from using any
drug that might be dangerous for a
mysdiagnosed psychiatric distur-
bance and often permits to adminis-
ter medications that can effica-
ciously control both headache and
psychiatric disorders.
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well as TTH by an increase of serotoninergic and/or nora-
drenergic pool that exerts a descending inhibiting modula-
tion of pain at the level of spinal dorsal horn/trigeminal
neurons. Antidepressive drugs can control also anxiety dis-
orders possibly associated with depressive symptoms: this
is true not only for the tricyclic antidepressants (TCAs) but
also for the serotonin selective reuptake inhibitors (SSRIs),
which lack the sedative effects of the TCAs but have a dif-
ferential advantage in treating anxiety within depression
probably by means of an induced normalisation in pro-
cessing information; certainly some differences exist in
sedative side effects of novel antidepressants: for example,
within SSRIs, fluvoxamine and sertraline are more seda-
tive and within mixed norepineprhine-serotonin reuptake
inhibitors (NSRI), mirtazepine has strong sedative proper-
ties; so, only one of these medications could improve at the
same time pain, depression and anxiety (Fig. 1). The anti-
depressive properties of anti-epileptic drugs (AEDs) and
the rapidly rising popularity of AEDs in preventive
migraine treatment give one more good opportunity for a
pharmacological approach to both diseases by only one
drug with a greater safety when using new AEDs such as
topiramate. Particularly, valproate can be useful when the
depressive syndrome is of sufficient severity to satisfy the
criteria for major depression.
In the cluster of anxiety-related headaches, generalised
anxiety disorder (GAD) represents the most frequent dis-
order. Benzodiazepines (BZDs) act at specific BZD recep-
tors to enhance the binding of the inhibitory neurotrans-
mitter GABA with a following improvement of anxious
symptoms; but GABAergic neurons have been also shown
in the dorsal horn and in trigeminal caudalis nucleus to
receive nociception inputs, so as to exert presynaptic con-
trol on ascending pain [3]; therefore, BZDs can raise the
Fig. 1 Preventive treatment in
headache associated with depressive
syndrome
Fig. 2 Preventive treatment in
headache associated with panic dis-
order
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pain threshold due to a GABAergic modulation of endor-
phinergic or serotoninergic/noradrenergic activity; more-
over, in TTH, myorelaxation potentiation associated with
some BZDs like diazepam may play an important role in
the improvement of pain. So, both GAD and TTH can take
advantage of the administration of BZDs, but long-term
therapy with BZD is not eligible in the aim of avoiding
tolerance. As regards the preventive treatment of this
association, the beta-blockers can aid both migraine and
GAD because of intrinsic anxiolytic property of these
medications; flunarizine can be used too, owing to its
sedative side effect.
GAD is not the only anxiety disorder which may be
related to headache. Panic disorder has been shown to be
associated with TTH as well as migraine [1, 2]. In the first
case, the short-term intake of BZDs like alprazolam can
be efficacious in both disorders; in the second case, val-
proate (VPA) can be used due to its property of inhibiting
migraine “hyperexcitabilty state” by means of a potentia-
tion of glutamate-decarboxylase enzyme and resulting
decrease of glutamate pool. As a great number of patients
with panic disorder suffer also from depression, the asso-
ciation of panic disorder with TTH or migraine can show
benefits when treated with TCAs or SSRIs/NSRIs. The
SSRIs are first choice medications also for long-term
treatment of TTH+panic disorder without mood disorders,
because positive results have been seen in the treatment of
panic disorder with these drugs in agreement with the
demonstrated efficacy on anxiety symptoms. The associa-
tion between migraine and panic disorder and bipolar dis-
order or unipolar disorder can be treated with VPA, which
is effective in the control of panic (Fig. 2).
Obsessive-compulsive disorder was not found in TTH
patients and was found only in migraineur females (5%); the
administration of SSRI can improve both headache and this
anxiety disorder; when obsessive-compulsive disorder is
also associated with a major depressive disorder, the treat-
ment is different according to whether this is a unipolar dis-
order or a bipolar disorder; in the first case, the dose of SSRI
can be lower and a replacement of SSRI with NSRI may be
considered; in the second case, the intake of SSRI must be
stopped and an antimaniacal treatment must be started.
When psychiatric comorbidity of TTH and migraine
consists of somatoform disorder, the antidepressive drugs
are the medications of first choice.
In conclusion, it becomes possible to draw up some
useful flow-charts of pharmacological management for
psychiatric comorbidity in headache patients.
A good knowledge of the right management of psy-
chiatric comorbidity in headache represents the only
card which may be played by clinicians in the aim of
breaking the “psycho-neuro-biochemical loop”: really,
as any psychological disorder can affect the onset and
the course of somatic disorders which in turn can
increase psychiatric vulnerability [4], the misdiagnosis
of a psychiatric comorbidity might lead to a progressive
worsening of headache or to its dangerous transforma-
tion into a chronic form.
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